Feed / ACAD

ACADIA Pharmaceuticals Inc.

ACAD

Healthcare · 29.51 +1.6% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

ACADIA Pharmaceuticals Inc.'s move is being confirmed by its market group.

ACAD accounts for 13.6% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveCounter-move#3 of 12 by movement share
Group movement share13.6%Absolute path energy—not portfolio weight
Relative path+0.94%counter
Effective breadth7.8 / 12broad
Relative alignment6/12downside path · 4 counter-moving
Capital-flow agreement41%not yet clean
SEQUENCE READ

MRK moved materially before ACAD. ACAD crossed its material path threshold at 10:40 ET. EXEL, BMY, NBIX followed.

What changed
  • Revenue increased 16.4% versus the comparable filing period.
EVIDENCE COVERAGE

8 of 15 members in Biopharmaceuticals and Care are active. 0 of 3 disclosed connections are confirming.

What would change this read
  • At least 10 of 15 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABBV begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.

Watch this read

Who this business touches

The relationships behind ACAD

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

STOKStoke Therapeutics, Inc.partnerMay 7, 2026 ▾

“In January 2022, the Company entered into a license and collaboration agreement with Stoke Therapeutics, Inc.”

Depended on by

STOKStoke Therapeutics, Inc.partnerMar 16, 2026 ▾

“In addition, although we intend to establish a sales organization if we are able to obtain approval to market any product candidates, we have entered into a strategic alliance with Biogen to develop and commercialize zorevunersen outside of North America (the…”

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ACAD is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.